Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
|ClinicalTrials.gov Identifier: NCT00455702|
Recruitment Status : Completed
First Posted : April 4, 2007
Results First Posted : August 7, 2014
Last Update Posted : August 7, 2014
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: d-cycloserine||Phase 4|
This is a ten-week, parallel-group, placebo-controlled trial examining the cognitive effects at weeks 1, 2, 3. 4, 5, 6, 7, 8 & 10 of once-weekly oral D-cycloserine 50 mg added to a stable dose of antipsychotic for 8 weeks in 60 adult outpatients with schizophrenia.
- Assess the effects of a single dose of D-cycloserine 50 mg on cognitive functioning compared to placebo.
- Assess the effects of repeated weekly dosing of D-cycloserine on cognitive functioning at week 8 compared to placebo.
- Assess the effects of repeated weekly dosing of D-cycloserine on memory functioning once a week 1 hour after medication administration compared to placebo.
- Assess the persistence of learned information in a no-treatment follow-up assessment at Week 10 in the D-cycloserine group compared to the placebo group.
- Assess effects of weekly D-cycloserine dosing on positive & negative symptoms at week 8 compared to placebo.
- Assess tolerability and side effects of weekly D-cycloserine compared to placebo.
- Assess the effects of d-cycloserine dosed weekly for seven weeks on reward responsiveness as measured with the response bias task compared with placebo.
- Assess the effects of d-cycloserine dosed weekly for seven weeks on measures of functioning.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||38 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals|
|Study Start Date :||July 2004|
|Actual Primary Completion Date :||April 2007|
|Actual Study Completion Date :||April 2007|
50 mg d-cycloserine
50mg dose d-cycloserine v placebo
Placebo Comparator: Placebo
50 mg placebo
50mg dose d-cycloserine v placebo
- Main Outcome Measure: The Change From Baseline to Week 8 on the SANS [ Time Frame: Baseline score vs. Week 8 ]The change from baseline to week 8 on the scale for the assessment of negative symptoms (SANS) total score. Total SANS scores range from 0-100. The SANS is comprised of 5 subscores: Affective Flattening or Blunting (score range 0-35), Alogia (score range 0-20), Avolition-Apathy (score range 0-15), Anhedonia-Asociality (score range 0-20), and Attention (0-10). For each scale, the higher the score the more prominent the negative symptoms were. The total score was computed by adding all the subscale total scores. To compute change in scores, week 8 scores were subtracted from baseline scores, resulting in a change score. Higher values equals greater improvement (i.e. week 8 score was lower than baseline score).
- Treatment Effects on the Positive Syndrome Subscale of the PANSS [ Time Frame: Baseline score vs. Week 8 score ]The change from baseline to week 8 on the positive symptom sub-scale of the Positive and Negative Syndrome Scale (PANSS). Total PANSS positive symptom sub-scale scores range from 7-49. The PANSS positive symptom sub-scale is comprised of 7 items rated on a scale of 1-7: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. A score of one on each item 1 absent, 2 is minimal, 3 is mild, 4 is moderate, 5 is moderately severe, 6 is severe, and 7 is extreme. The total score was computed by adding all the items on the sub-scale together. To compute change in scores, week 8 scores were subtracted from baseline scores, resulting in a change score. Higher values equals greater improvement (i.e. week 8 score was lower than baseline score).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00455702
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Donald C Goff, M.D.||Massachusetts General Hospital|